Zevra Therapeutics (ZVRA) Total Non-Current Liabilities (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Total Non-Current Liabilities data on file, last reported at $70.9 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 38.61% year-over-year to $70.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $70.9 million (down 38.61% YoY) and the FY2025 annual result came in at $123.0 million, up 1.98% from the prior year.
• Total Non-Current Liabilities eased to $70.9 million in Q1 2026, from $123.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $135.7 million in Q2 2025 to a low of -$8.5 million in Q1 2022.
• A 5-year average of $81.8 million and a median of $94.1 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The widest YoY moves for Total Non-Current Liabilities: up 593.97% in 2022, down 237.36% in 2022.
• Tracing ZVRA's Total Non-Current Liabilities over 5 years: stood at $40.2 million in 2022, then surged by 134.76% to $94.4 million in 2023, then rose by 27.86% to $120.7 million in 2024, then rose by 1.98% to $123.0 million in 2025, then tumbled by 42.37% to $70.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $70.9 million (Q1 2026), $123.0 million (Q4 2025), and $133.0 million (Q3 2025), per Business Quant data.